Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Friday, August 7, 2026

Snapshot: Aug 7, 2026 · 6:00 PM 100 stocks analyzed

Strong Up Day

Fri, Aug 7, 2026 Tech Rally High

Tech rallied hard with NASDAQ +5.2% leading a broad market surge, while high dispersion saw healthcare stocks dominate gainers and earnings beats fuel individual names to 90%+ g…

60% NASDAQ Composite jumped 5.19% and NASDAQ-100 surged 5.12%, outpacing S&P 500's +3.58% gain in a decisive tech-led rally that defined the day's broad upside momentum alongside strong small-cap participation.
25% High single-stock dispersion with extreme top-end moves—50 gainers averaging +30.7% led by WWR's 91.6% surge and GENVR's 58.5% jump on Gen Digital's earnings beat and raised guidance—while healthcare names claimed 34% of winners and drove earnings-driven outperformance.
15% Losers saw healthcare sector concentration at 36% with severe casualties including a 95.7% crash in ARCI and multiple 20%+ declines tied to earnings misses and guidance cuts (SEZL, CVRX, TTD, QDEL), offsetting broad market strength for a classic divergent action day despite the up tape.

Healthcare drove 34% of gainers 5 names returned after long absences SXTC · 3-day losers streak WWR — first appearance HUDI — first appearance

Market Regime

Fri, Aug 7, 2026 Risk-On conf: medium macro · prototype

+52

Tailwind −100 … +100 · + tailwind / − headwind

VIX14.9 p1 Drawdown0.0% Held5d · building SinceAug 3

Top drivers: VIX percentile ▲ S&P vs 20d avg ▲ S&P vs 50d avg ▲

processId: history-market-regime

Market Indexes

Fri, Aug 7, 2026 13

S&P 500

7,757.64

+267.92

+3.58%

Dow Jones

54,036.93

+1,551.90

+2.96%

NASDAQ Composite

26,690.62

+1,316.77

+5.19%

NASDAQ 100

29,722.30

+1,448.10

+5.12%

DJ US Total Market

76,854.08

+2,747.26

+3.71%

Russell 1000

4,227.99

+151.61

+3.72%

S&P MidCap 400

3,885.57

+126.93

+3.38%

Russell 2000

3,034.49

+103.15

+3.52%

Russell 2500

1,298.00

+15.12

+1.18%

Russell 3000

4,414.12

+157.94

+3.71%

Nasdaq Financial-100

7,519.34

+14.75

+0.20%

NIFTY 50

24,570.65

−203.65

-0.82%

VIX

14.90

−0.96

-6.05%

Biggest Gainers

Fri, Aug 7, 2026 50

WWR

Westwater Resources IncBasic Materials

$0.76+$0.37

+91.6%

NYSE · Mkt cap $73 M

Westwater Resources surged 91.57% on August 7, 2026, but no news headlines were available in the prior 48 hours to explain the jump, making the specific catalyst unclear.

No recent news was found in the provided headlines for the last 48 hours, so the driver of this dramatic single-day gain cannot be directly attributed to a reported event. Westwater Resources is a uranium and critical minerals exploration and development company, and stocks in this sector are historically sensitive to several catalysts including uranium spot price movements, nuclear policy developments, funding announcements, exploration results, or shifts in investor sentiment around energy transition demand. Given the magnitude of the move and absence of news, this could represent a technical bounce from oversold conditions, a delayed market reaction to an earlier announcement not captured in the RSS feed, or broader sector momentum. Without accompanying headlines or intraday volume data, pinpointing the exact trigger is not possible.

XHLD

TEN Holdings, Inc. Common StockCommunication Services

$2.02+$1.16

+61.7%

NASDAQ · Mkt cap $92 M

No news headlines were found in the last 48 hours, so the 61.70% surge in XHLD cannot be attributed to a specific announced catalyst; the move likely reflects technical trading activity, delayed news dissemination, or market speculation.

The absence of recent news headlines is notable given the magnitude of the gain. A jump of this size typically correlates with a specific catalyst such as earnings results, merger or acquisition news, regulatory approval, or significant contract announcements. For a micro-cap stock like TEN Holdings, the spike could reflect short-covering activity, a delayed reaction to previously unreported company developments, retail trading interest or coordination, or even a technical rebound if the stock had been heavily oversold. Without access to the actual headlines or company filings from the snapshot date, attributing the move to any particular corporate event would be speculation. It is also possible that news exists but was not captured in the Yahoo Finance RSS feed used for this analysis.

GENVR

Gen Digital Inc. Contingent Value Rights

$3.94+$1.48

+58.5%

NASDAQ

Gen Digital reported Q1 earnings that beat estimates with strong bookings growth and raised full-year guidance, directly driving the GENVR contingent value rights holder upside as the parent company's improved outlook increases CVR payout probability.

Gen Digital (GEN) announced Q1 fiscal 2027 results on August 7 that exceeded both earnings and revenue estimates by 2.90% and 2.54% respectively, reported double-digit bookings growth at 11%, and raised its full-year fiscal 2027 guidance. The company cited strong marketplace performance and AI-driven innovation as drivers, with revenue growing at the fastest rate since inception. For GENVR contingent value rights holders, a raised guidance and beat earnings signal improved near-term cash generation and higher probability of triggering any earn-out conditions attached to the CVR structure. This makes the contingent payment more likely and potentially larger, explaining the 58.50% spike as warrant/CVR holders repriced upward risk of payout acceleration.

SOAR

Volato Group, Inc.Industrials

$0.14+$0.07

+49.1%

NYSE · Mkt cap $7.8 M

No news headlines are available for the past 48 hours, so the 49% gain on SOAR cannot be attributed to a specific announced catalyst. The move is likely driven by technical factors, retail momentum, or untracked news on smaller exchanges.

Volato Group (SOAR) rose 49% to $0.14 on August 7, 2026, but no headlines from the past 48 hours are available to explain the move. At this price level and market cap, the stock likely qualifies as a micro-cap or penny stock, which are prone to sharp moves on minimal volume, short covering, or retail trading momentum unrelated to fundamental news. Possible explanations include a delayed press release not yet indexed by Yahoo Finance, technical rebound after selling pressure, insider activity, or social media attention. Without access to press releases, SEC filings, or real-time market data beyond headlines, pinpointing the specific trigger is not possible from the evidence provided.

HUDI

Huadi International Group Co., Ltd.Basic Materials

$0.72+$0.30

+42.9%

NASDAQ · Mkt cap $13 M

No news headlines were found in the last 48 hours, so the 42.88% gain likely stems from technical trading, a delayed announcement, or market rumors rather than a disclosed corporate event.

The absence of recent news in Yahoo Finance RSS combined with a substantial single-day gain suggests the move was driven by factors other than published headline news. For a micro-cap stock like HUDI trading at $0.72, common catalysts include short-squeeze dynamics, technical breakouts above key resistance levels, over-the-counter market rumors, insider activity announcements, or delayed earnings or guidance releases that may not yet be indexed in major financial RSS feeds. Penny stocks and small-cap international holdings are particularly prone to volatility spikes unaccompanied by immediate news visibility, especially if they have a history of retail interest or low float. Without access to regulatory filings, press releases, or social media sentiment, we cannot pinpoint the specific trigger, but the magnitude of the move suggests something meaningful to investors occurred.

ONVO

Organovo Holdings IncHealthcare

$0.47+$0.14

+41.8%

NASDAQ · Mkt cap $572 K

No news headlines were found in the last 48 hours to explain ONVO's 41.82% jump, so the catalyst remains unknown and could reflect a technical bounce, delayed disclosure, or market rumor.

ONVO exhibited a significant single-day rally ranking sixth among NASDAQ gainers, but the Yahoo Finance RSS feed returned no headlines in the preceding 48 hours that would account for this move. Organovo is a biotech/regenerative medicine company whose stock price historically responds to clinical trial updates, partnership announcements, or regulatory developments. The absence of reported news suggests either a delayed market reaction to an older announcement, a technical rebound after oversold conditions, short covering, or an unconfirmed rumor or social media catalyst that had not yet been picked up by major news outlets at the time of snapshot. Without access to the full newswire or company disclosures from August 5-7, 2026, it is not possible to identify the specific trigger with confidence.

QNST

QuinStreet IncCommunication Services

$21.09+$5.93

+39.1%

NASDAQ · Mkt cap $1.1 B

QuinStreet delivered record Q4 2026 results with 43% revenue growth, 87% EBITDA expansion, and beat earnings and revenue estimates, triggering strong investor enthusiasm and driving the 39% gain.

QuinStreet reported fiscal fourth-quarter and full-year 2026 results on August 6 that exceeded Wall Street expectations on both earnings and revenue lines. The company posted 43% revenue growth to $373.9 million with robust double-digit growth across financial services and home services verticals, plus an 88% jump in home services revenue. Adjusted EBITDA expanded 87%, demonstrating significant operating leverage. The earnings surprise was 13.64% and revenue surprise 3.86%, both positive. The stock jumped 28% immediately after results and continued climbing, likely as investors digested the strength of the guidance and forward-looking momentum in both core verticals. This is a textbook earnings-driven rally triggered by both beat-and-raise fundamentals and accelerating growth in high-demand sectors.

AHPA

Avista Public Acquisition Corp. II

$3.08+$0.84

+37.5%

SENS

Senseonics Holdings IncHealthcare

$7.03+$1.91

+37.2%

NYSE · Mkt cap $523 M

Senseonics reported Q2 revenue growth of approximately 120% year-over-year, beat guidance expectations, and raised its full-year 2026 revenue outlook, driving the 37% gain.

Senseonics released second-quarter 2026 results on August 6-7 showing strong operational momentum. The company reported Q2 revenue of $14.5 million, representing roughly 120% year-over-year growth and beating prior guidance. Management also raised full-year 2026 revenue guidance to $62-66 million from the previous range of $60-64 million, and highlighted record organic gross margins. While the company posted a net loss (with earnings surprise of -14.55%), the revenue surprise of +10.73% combined with margin expansion and upside guidance revision typically drive positive stock reactions in growth-stage medical device companies. The headline about increased investment costs explains the net loss widening despite strong top-line performance, which investors appear willing to tolerate given the growth trajectory and margin profile. This is a classic earnings-driven catalyst for a small-cap biomedical company.

RCEL

Avita Medical LtdHealthcare

$7.80+$2.10

+37.2%

NASDAQ · Mkt cap $320 M

Avita Medical surged 37% after reporting Q2 2026 revenue of $21.7 million (up 18% year-over-year, beating expectations) and raising full-year guidance to $86–$89 million while projecting cash flow breakeven by Q4 2026.

The stock's strong gain is grounded in a clear earnings beat and positive forward guidance revision. Q2 revenue of $21.7 million exceeded analyst expectations and grew 18% annually plus 13% sequentially, driven by the company's RECELL wound-care product and newer portfolio offerings. Most significantly, management raised full-year 2026 revenue guidance and telegraphed a path to cash flow breakeven by the fourth quarter, a milestone that typically signals approaching profitability for investors in regenerative medicine companies. The premarket jump of 21.7% reflects immediate market recognition of these results, with the additional 15+ percentage points likely accumulating through the regular session as investors reassess the company's trajectory. The Canaccord conference participation announcement is secondary context but reinforces investor interest.

EXFY

Expensify, Inc.Technology

$2.70+$0.72

+36.0%

NASDAQ · Mkt cap $222 M

Expensify reported Q2 2026 earnings on August 6-7 showing narrowed losses, raised full-year guidance, and 250% surge in its AI-powered New Expensify platform, driving the +36% rally.

The earnings announcement released on August 6, 2026 provided three concrete positive catalysts. First, management narrowed net losses and raised full-year guidance, signaling improved profitability trajectory. Second, the AI-driven New Expensify platform posted a 250% growth rate, demonstrating strong traction in the company's strategic pivot toward modern, AI-focused expense management. Third, management highlighted continued improvements in cash generation despite legacy product churn, suggesting the business model is shifting toward higher-value, faster-growing offerings. The earnings call highlights published August 7 morning amplified these messages. For a stock trading at $2.70 with prior volatility, a beat on profitability improvement combined with three-digit growth in the flagship new product and raised guidance represents a material positive surprise that justifies a 36% single-day gain.

CRSR

Corsair Gaming IncTechnology

$14.38+$3.76

+35.4%

NASDAQ · Mkt cap $1.4 B

Corsair Gaming surged 35% following strong Q2 earnings with higher margins, improved profitability, and a raised full-year 2026 outlook, combined with a analyst fair-value upgrade from $8.81 to $10.22.

The evidence directly supports the move. Corsair reported better-than-expected Q2 results marked by margin expansion, improved profitability, and substantially stronger operating cash flow. The company also raised its full-year 2026 guidance. Within hours, multiple analysts reset their expectations upward, with the modeled fair value rising approximately 16% to $10.22. These are classic catalysts for large single-day moves in gaming hardware stocks. The broader market tailwind—with the Nasdaq leaping on declining Fed rate-hike odds—likely provided additional momentum. However, the stock's rise to $14.38 substantially exceeds the new analyst fair value of $10.22, suggesting either aggressive short-covering, momentum buying, or market expectations that analyst models have not yet fully absorbed the earnings beat or guidance raise.

OABI

OmniAb, Inc.Healthcare

$3.06+$0.80

+35.4%

NASDAQ · Mkt cap $691 M

OmniAb reported Q2 earnings on August 6 with revenue surging 243%, beating estimates by 150%, while raising full-year 2026 guidance to $32M-$36M on strong milestone payments from partner programs, driving the 35% gain on August 7.

The stock's jump is directly attributable to a strong earnings beat and forward guidance raise. Headlines establish that OmniAb delivered a 149.67% revenue beat versus expectations, with Q2 revenue surging 243% year-over-year driven by milestone payments from partner programs. The company also raised full-year 2026 revenue guidance and improved its year-end cash outlook. Additionally, a recent announcement that VERAXA Biotech advanced its VXA-222 program following completion of the discovery phase with OmniAb suggests active partner momentum and revenue-generating milestones. For a biotech services and discovery platform company, beating on revenue by this margin, raising guidance, and demonstrating partner program execution represents a material positive catalyst that typically justifies a significant single-day rerating upward.

TEAM

Atlassian Corp PLCTechnology

$149.05+$38.77

+35.2%

NASDAQ · Mkt cap $45 B

Atlassian reported a fourth-quarter earnings beat with 28% revenue growth and 31% cloud revenue growth, plus AI user base exceeding one million, directly addressing investor concerns that AI could weaken its products and prompting a founder stock buyback pledge.

The headlines establish that Atlassian released fourth-quarter fiscal 2026 earnings on August 7, 2026, with revenue reaching $1.8 billion (28% growth) and cloud revenue hitting $1.2 billion (31% growth), both topping analyst expectations. The company also provided stronger-than-expected cloud revenue guidance. A distinct narrative thread runs through multiple headlines: investors had feared generative AI would cannibalize Atlassian's core products, but the earnings call revealed AI integrations had reached one million users and were accelerating rather than competing with the business. This directly dispelled bearish sentiment. Additionally, founder stock buyback announcement of up to $250 million signals management confidence. The broader market rally on weak July jobs data and falling interest rates provided a tailwind, but the stock-specific catalysts are clear and fundamental in nature.

NCOOR

Southern Cross Acquisition I Corp. Rights

$0.20+$0.05

+33.3%

NASDAQ

No news headlines were found in the last 48 hours, but NCOOR is a SPAC rights offering which can experience volatile price swings on low trading volume and speculative positioning unrelated to traditional corporate catalysts.

The stock jumped 33 percent on a single day with no material news reported in the prior 48 hours. NCOOR is a rights offering tied to Southern Cross Acquisition I Corp., a special purpose acquisition company. Rights offerings and SPAC-related securities are thinly traded and highly sensitive to redemption flows, warrant arbitrage activity, merger speculation, and technical factors such as short covering or algorithmic trading. On very low dollar volume, even modest absolute buying pressure can produce outsized percentage gains. The absence of news headlines suggests the move may be driven by internal SPAC mechanics, positioning adjustments, or technical trading rather than a discrete corporate announcement or business development.

BEAGR

Bold Eagle Acquisition Corp. Right

$0.33+$0.08

+32.8%

NASDAQ

No news headlines were available in the last 48 hours, so the 32.80% gain on BEAGR cannot be attributed to a specific announced event. The move may reflect technical trading activity, delayed news absorption, or SPAC-related developments.

Bold Eagle Acquisition Corp. Right (BEAGR) is a SPAC rights security with minimal liquidity and low absolute price, making it susceptible to outsized percentage moves on modest dollar volume. Without any news headlines in the last 48 hours, the jump cannot be tied to a named catalyst such as an earnings release, merger announcement, regulatory approval, or guidance change. The most likely explanations for this type of stock are either technical trading (short covering, options expiration mechanics, or retail flow) or a delayed market reaction to earlier developments in the parent SPAC or its proposed merger target. SPAC-related securities are also prone to volatility as deal timelines shift or stakeholder votes approach.

SPCM

Sound Point Acquisition Corp I, LtdFinancial Services

$14.18+$3.46

+32.7%

PUBM

PubMatic IncTechnology

$17.80+$4.37

+32.5%

NASDAQ · Mkt cap $752 M

PubMatic surged 32.5% following a better-than-expected Q2 earnings report with 11% revenue growth, a 300% earnings beat, and momentum in connected TV and mobile, reversing prior guidance misses and signaling stronger-than-anticipated demand recovery.

PubMatic reported Q2 2026 earnings and revenue that significantly exceeded Wall Street estimates, delivering a 300% earnings surprise and 13.74% revenue beat on sales of $78.59 million, up 10.5% year-over-year. The company cited acceleration in high-margin formats including connected TV and mobile applications, alongside rapid adoption of its Agentic OS platform. Critically, the company returned to double-digit revenue growth ahead of prior expectations, suggesting management had been overly conservative in prior guidance. The timing is particularly important because competitor The Trade Desk reported weak Q2 results the same day, making PubMatic's strong performance stand out. One offsetting item is the announcement of CFO Steve Pantelick's planned retirement, which typically carries some negative sentiment, but the earnings strength clearly dominated market reaction. The 32.5% jump ranks PUBM among the day's largest gainers.

AIFA

All In FutureTech Alliance, Inc.Technology

$2.01+$0.51

+32.5%

NASDAQ · Mkt cap $19 M

No news headlines were published in the last 48 hours for AIFA, so the 32% gain cannot be attributed to a specific announced event; the move likely reflects either delayed market reaction to earlier news, technical trading, or speculative positioning.

The absence of any headlines in the most recent 48-hour window is striking given the stock's strong 32% gain and top-20 ranking among daily gainers. This suggests the catalyst either (1) occurred before the 48-hour lookback and is only now being priced in by the market, (2) stems from a technical or sentiment-driven event such as a short squeeze, options expiration effect, or momentum spike that does not rely on fundamental news, or (3) involves rumors or social media discussion not yet captured in formal news feeds. Without access to older headlines, company filings, short float data, or intra-day trading volumes, it is impossible to determine which mechanism is at play. For a micro-cap or speculative technology stock like AIFA, sharp unattributed gains are not uncommon and often revert quickly absent a subsequent news announcement.

MTW

Manitowoc Co Inc-TheIndustrials

$18.82+$4.58

+32.2%

NYSE · Mkt cap $737 M

Manitowoc reported record orders (56% surge), expanded EBITDA margins by 330 basis points, and raised full-year guidance, triggering the 32% single-day gain as investors repriced growth and profitability expectations.

The earnings headlines from August 6-7 establish a clear catalyst: Manitowoc delivered substantially better-than-expected second-quarter results with a 56% order surge, 85.9% improvement in adjusted EBITDA year-over-year, and a backlog exceeding $1.0 billion. Management raised full-year guidance on the back of these gains. The 330 basis point margin expansion is particularly significant for a cyclical industrial manufacturer, signaling operational leverage and pricing power. A 32% single-day move is extreme but proportionate to the magnitude of the beat and the upward revision to forward earnings, especially if the stock had been undervalued or the market's prior expectations were materially lower. This is a straightforward earnings-driven rally.

TOI

The Oncology Institute, Inc.Healthcare

$6.41+$1.37

+27.1%

NASDAQ · Mkt cap $620 M

TOI ticker collision: The headline references Topicus.com Inc. (TSXV:TOI, a Canadian software company), not The Oncology Institute (NASDAQ:TOI). The +27% move likely reflects a delayed market reaction to Topicus's Q2 2026 earnings announcement, not oncology sector news.

The provided headline announces Q2 2026 financial results for Topicus.com Inc., a Canadian publicly listed software company owned by Constellation Software. However, the stock ticker TOI on NASDAQ refers to The Oncology Institute, a completely different U.S. healthcare company. This appears to be a data mismatch in the news feed. If the headline were actually reporting on The Oncology Institute's earnings or clinical results, the snapshot date of 2026-08-07 would align with a potential earnings release around August 5. Without confirmed news specific to The Oncology Institute's fundamentals, guidance, pipeline, or clinical outcomes, the cause of the 27% surge remains unclear. Large single-day moves in smaller healthcare stocks can result from clinical trial announcements, regulatory decisions, partnership news, or short-squeeze activity.

FIGS

FIGS, Inc.Consumer Cyclical

$14.24+$2.99

+26.6%

NYSE · Mkt cap $2.4 B

FIGS reported Q2 2026 earnings and revenues that significantly beat Wall Street estimates, with EPS up 57.14% and revenue up 5.66%, plus raised full-year 2026 guidance, driving a +26.58% single-day rally.

FIGS released second-quarter 2026 results on August 6 that substantially exceeded consensus expectations. Revenue reached $196.6 million, up 28.8% year-over-year, topping estimates by 5.66%. Earnings per share came in at $0.15 on a GAAP basis, representing a 57.14% beat versus Wall Street's EPS forecast. Multiple news sources highlighted that the results were "impressive" and "comfortably exceeded" analyst expectations. Critically, the company also raised its full-year 2026 outlook alongside the earnings release, a positive forward signal that typically drives investor confidence and justifies upward price revisions. The stock rallied approximately 25-27% in premarket trading on August 7 and closed up 26.58%, making it the 22nd largest gainer of the day. This is a textbook positive earnings surprise with raised guidance scenario.

SPT

Sprout Social IncTechnology

$10.33+$2.15

+26.3%

NASDAQ · Mkt cap $689 M

Sprout Social beat both Q2 earnings and revenue expectations with a 62.5% EPS surprise and 1.35% revenue beat, while raising operating income guidance, triggering the 26% single-day surge.

The earnings release on August 6-7 shows Sprout Social delivered Q2 revenue of $123.8 million, up 10.8% year-over-year, exceeding analyst projections. More significantly, the company posted a 62.50% earnings surprise, substantially outperforming consensus EPS estimates. Concurrent with these results, management raised operating income guidance and highlighted strong momentum in its customer base, with subscription revenue from customers earning $30K+ ARR growing 20% year-over-year. The company is also navigating an intentional 20% workforce reduction and beginning early monetization of its Trellis AI platform, both of which appear to be positioning it for profitable growth. The combination of the large EPS beat, revenue outperformance, and raised forward guidance created a compelling catalyst for institutional and retail buyers, explaining the outsized gain.

UAVS

AgEagle Aerial Systems IncTechnology

$0.91+$0.19

+26.2%

NYSE · Mkt cap $57 M

No news headlines were found in the last 48 hours, so the 26% gain likely reflects either a technical or sentiment-driven move, delayed reaction to prior news, or a small-cap volatility event.

AgEagle Aerial Systems is a micro-cap drone and aerial imaging company trading at $0.91, making it highly susceptible to technical moves, short-covering rallies, and sentiment swings on low volume. The absence of news in the most recent 48 hours suggests the catalyst was not a fresh announcement captured by major news feeds. Possible explanations include a reversal after oversold conditions, accumulation by a strategic buyer or insider, news that has not yet propagated to Yahoo Finance RSS, or a delayed market reaction to an older announcement. Micro-cap stocks in the defense and drone sector can also experience volatility tied to geopolitical events or sector-wide sentiment shifts that move multiple names without issuing individual company headlines.

EMBC

Embecta Corp.Healthcare

$4.40+$0.90

+25.6%

NASDAQ · Mkt cap $307 M

Embecta beat Q3 revenue expectations with a $50 million sequential jump, raised adjusted EPS guidance, and advanced its Owen Mumford integration, driving the 25.6% gain despite persistent U.S. market headwinds.

The earnings release and earnings call highlights confirm Embecta delivered a material sequential revenue beat and raised forward guidance on adjusted earnings per share, which are the primary drivers of a 25% single-day move. The company reported Q3 fiscal 2026 revenue of approximately $272 million, which represented a year-over-year decline in reported and constant-currency terms, yet the sequentially strong recovery and guidance raise signal improving operational momentum and management confidence. The announcement also included a quarterly cash dividend of $0.01 per share, reflecting capital discipline. Despite acknowledged U.S. market pressures and the company's transition from a pure insulin-delivery business to a broader medical supplies company, investors rewarded the near-term beat and forward EPS visibility. The 25.6% gain ranks among the day's largest, consistent with an earnings surprise that reset market expectations for profitability trajectory.

CSAI

Cloudastructure, Inc. Class A Common StockTechnology

$7.24+$1.45

+25.0%

NASDAQ · Mkt cap $4.5 M

Cloudastructure announced on August 6 that it won a full guard replacement contract across five buildings for a major Southern California commercial real estate portfolio, driving a 25% single-day gain on expanded AI-powered remote guarding adoption signals.

The August 6 news announcement describes a concrete commercial win: Cloudastructure secured a full guard replacement contract for a five-building Southern California office portfolio belonging to one of the world's largest commercial real estate firms. The headline emphasizes that this expansion followed a direct referral from another property within the same institutional tenant's portfolio, suggesting product-market fit and repeat business confidence. The framing around growing adoption of AI-powered remote guarding across commercial real estate suggests this deal validates Cloudastructure's core value proposition in a large addressable market. For a smaller-cap AI and automation-focused company, a named multi-building enterprise contract with an institutional customer can signal meaningful revenue trajectory and operational traction, which typically triggers near-term equity appreciation if the market views it as evidence of scalable demand.

GTN

Gray Television IncCommunication Services

$5.36+$1.07

+24.9%

NYSE · Mkt cap $515 M

Gray Media reported a massive earnings beat driven by strong political advertising revenue in Q2 2026, with earnings topping estimates by 362.50% and revenues up 8.7% year-over-year, spurring the 25% gain.

Gray Media announced Q2 2026 results on August 7 that substantially exceeded Wall Street forecasts. The company delivered a 362.50% earnings surprise and 6.47% revenue surprise, with total revenue reaching $839 million, up 8.7% year-over-year. The earnings beat was explicitly attributed to a surge in political advertising revenue, which historically drives cyclical strength in local broadcasting. The company also announced a quarterly cash dividend of $0.08 per share, signaling management confidence in cash generation. For a broadcaster with a challenged capital structure, a beat of this magnitude—especially one tied to a high-margin revenue stream like political ads—typically justifies a sharp revaluation higher. The magnitude of the move reflects relief and optimism that the business is delivering tangible earnings power.

ONTX

Onconova Therapeutics IncFinancial Services

$19.74+$3.94

+24.9%

BEEP

Mobile Infrastructure Corporation Common StockIndustrials

$2.54+$0.51

+24.9%

NASDAQ · Mkt cap $109 M

Mobile Infrastructure Corporation announced receipt of a preliminary non-binding indication of interest from Bombe Asset Management on August 6th, likely sparking the 24.88% single-day gain as investors reacted to potential strategic interest in the parking infrastructure owner.

The most relevant headline is Mobile Infrastructure's August 6th announcement of receiving a preliminary, non-binding indication of interest from Bombe Asset Management. While the press release text is truncated in the provided snippet, such announcements typically signal potential acquisition interest, partnership opportunities, or investment proposals that can trigger significant upside moves in smaller-cap stocks. The timing aligns perfectly with the price action on August 7th. The second headline about Sunrise Realty Trust's earnings miss appears unrelated to BEEP and does not explain the move. Without full details on Bombe's proposal terms or strategic rationale, we cannot assess probability of completion, but the market's immediate 25% reaction suggests investors view the development as materially positive for shareholder value.

CHEK

Check Cap LtdHealthcare

$1.41+$0.28

+24.8%

NASDAQ · Mkt cap $49 M

No news headlines were available in the last 48 hours to explain the 24.78% gain in CHEK stock on August 7, 2026. The jump likely reflects either delayed market reaction to an untracked announcement, technical trading activity, or broader sector movement.

Check Cap Ltd (CHEK) posted a strong single-day gain of nearly 25% but without any news headlines from the prior 48 hours to anchor the move. This creates an explanation gap. For a small-cap medical device or diagnostics company like Check Cap, typical catalysts would include clinical trial results, regulatory approvals, partnership announcements, or earnings surprises. The absence of tracked headlines suggests either that the triggering event occurred before the 48-hour window, was released through channels not captured by the Yahoo Finance RSS feed, or that the move reflects short-covering, options expiration dynamics, or retail trading momentum in a low-priced name. Without confirming information, the cause remains speculative.

TWLO

Twilio IncTechnology

$241.29+$47.84

+24.7%

NYSE · Mkt cap $45 B

Twilio delivered a strong Q2 earnings beat with accelerated organic growth, raised full-year guidance, and achieved record free cash flow of $353 million, triggering a 24-31% rally alongside broader software sector strength driven by easing Fed rate-hike concerns.

The headlines establish that Twilio released Q2 earnings on August 7 that exceeded analyst expectations on both revenue and earnings, accompanied by upward revision of annual forecasts. Multiple sources specifically cite accelerated organic growth and record quarterly free cash flow of $353 million as drivers. The company also provided September quarter guidance above consensus. This earnings-driven rally occurred alongside a broader market tailwind from unexpectedly weak July payroll data, which reduced expectations for Federal Reserve rate hikes and boosted software stocks sector-wide. Atlassian, JFrog, and Cloudflare also surged on earnings the same day, suggesting sentiment shifted away from AI disruption fears toward rewarding fundamental business execution. The 24.73% gain sits within the reported range of 27-31% mentioned across headlines, confirming consistent reporting of the magnitude.

ECOR

ElectroCore IncHealthcare

$8.25+$1.61

+24.2%

NASDAQ · Mkt cap $97 M

ElectroCore reported Q2 2026 earnings on August 6-7 with 28% revenue growth to $9.5 million, beating estimates by 0.92%, and a narrower net loss, likely driving the 24% gain.

The company released second-quarter results showing strong top-line growth at 28% year-over-year, with net sales reaching $9.5 million versus $7.4 million in Q2 2025. The earnings call highlights and formal announcement both emphasized growth drivers including Veterans Affairs prescription sales and direct-to-consumer Truvaga sales expansion. Crucially, while the company posted a net loss of $3.1 million, that loss decreased 17% from the prior year quarter, and adjusted EBITDA losses improved 26%, signaling progress toward profitability. The stock beat revenue expectations by 0.92% and earnings expectations by 19.51%, which in biotech and medical device names often triggers strong gains despite continued losses, as investors reward improving unit economics and revenue acceleration. This appears to be a straightforward positive earnings surprise scenario.

PSIX

Power Solutions International, Inc.Industrials

$41.01+$8.00

+24.2%

NASDAQ · Mkt cap $934 M

Power Solutions International reported strong Q2 2026 earnings with $152.5M in net sales, $16.9M net income, and $0.73 diluted EPS, while reducing total debt by $30.8M in the quarter, likely driving the +24% gain.

The company announced second-quarter financial results on August 6, 2026, showing solid operational performance across multiple metrics. Net sales of $152.5 million and net income of $16.9 million represent tangible earnings delivery, while the $0.73 diluted EPS provides a clear per-share earnings figure for investors to evaluate. The debt reduction of approximately $30.8 million during a single quarter is particularly notable, suggesting strong cash generation and improved balance sheet health. For an industrial equipment supplier like PSIX, demonstrated profitability combined with deleveraging typically signals operational momentum and reduced financial risk, both of which are positive catalysts for equity appreciation. The stock's ranking as the 33rd biggest gainer on a market-wide basis indicates broad investor enthusiasm rather than isolated buying.

TGE.WT

The Generation Essentials Group

$0.18+$0.03

+24.1%

NYSE

No news headlines were available in the last 48 hours for TGE.WT, so the 24% gain cannot be attributed to a specific disclosed event; the move likely reflects technical trading, delayed news dissemination, or retail interest in a low-priced warrant.

The absence of recent news in the provided RSS feed makes it impossible to identify a concrete catalyst for the 24% surge. TGE.WT is a warrant, which typically exhibits higher volatility than the underlying equity and can be sensitive to momentum trading, short covering, or speculative positioning even on limited volume. Without access to real-time news, social media chatter, or intraday announcements, several inference-based categories remain plausible: the move could reflect a delayed announcement not yet indexed by Yahoo Finance RSS, technical breakout or support bounce, short squeeze in a thinly traded security, or retail broker activity. Warrants in particular are prone to outsized percentage moves on modest dollar volume, especially in sub-dollar price ranges.

AMPGZ

Amplitech Group, Inc. Series B Right

$0.93+$0.18

+24.0%

NASDAQ

No news headlines appeared in the last 48 hours, making the cause of the 23.98% gain unclear. The move may reflect technical trading, rights offering mechanics, or undisclosed developments affecting Amplitech's Series B right.

Amplitech Series B Right (AMPGZ) is a derivative security tied to the parent company's future equity issuance, and such instruments often exhibit volatility driven by factors beyond traditional fundamentals. Without headlines identifying a specific catalyst, the jump could stem from several plausible mechanisms: renewed interest in the underlying parent company, adjustments in the right's value relative to the common stock, technical momentum or short covering in a thinly traded security, or an announcement that has not yet been indexed by the news aggregator. Rights offerings themselves are sensitive to sentiment shifts regarding dilution expectations and the parent's perceived financial health. The absence of news does not rule out a real catalyst; it may simply indicate the information source has not captured the relevant announcement within the timeframe.

ZVZZT

$30.92+$5.92

+23.7%

BTG

B2Gold CorpBasic Materials

$5.04+$0.94

+22.8%

NYSE · Mkt cap $6.6 B

B2Gold jumped 22.8% after the Mali government granted an exploitation permit for the Menankoto project on August 7, a major regulatory milestone that de-risks the company's expansion plans.

The timing and magnitude of the move align directly with the Menankoto exploitation permit announcement released on August 7. This permit removes a key regulatory hurdle for B2Gold's development of the Menankoto deposit in Mali. The company had flagged in its August 6 Q2 earnings release that it expected the permit "in the near-term," so the next-day approval appears to have met or exceeded investor expectations. The same-day earnings miss on net income is overshadowed by this operational milestone, which signals progression of a future production asset. Notably, the news arrived after market open on the 7th and the stock jumped roughly in line with the headline claim of a 23% gain, suggesting market reaction was direct and immediate to the permit grant.

UPLD

Upland Software IncTechnology

$5.26+$0.98

+22.8%

NASDAQ · Mkt cap $13 M

Upland Software surged 22.78% following its inclusion in the 2026 Gartner Magic Quadrant for Customer Service Knowledge Management Systems, a recognition that validates its enterprise AI positioning and likely boosted investor confidence.

The headline published on August 6 announces that Upland Software has been named in the 2026 Gartner Magic Quadrant for Customer Service Knowledge Management Systems. This is a material validation from a widely-respected analyst firm that enterprises and procurement teams rely on when evaluating software vendors. Gartner Magic Quadrant placement, particularly a mention in a relevant enterprise category, typically signals competitive strength, market traction, and product-market fit. For a software company trading at this price level, such third-party endorsement can drive both institutional and retail buying interest. The timing of the stock's jump on August 7 aligns directly with the August 6 announcement, making this the most plausible catalyst for the gain.

CTEV

MultiPlan CorporationHealthcare

$32.55+$5.96

+22.4%

NYSE · Mkt cap $662 M

Claritev Corporation (CTEV) reported Q2 2026 earnings that beat expectations on both revenue and earnings, posted record bookings of $74 million driven by AI initiatives, and raised full-year guidance, triggering the 22% gain.

The stock rallied on the strength of Claritev's August 7 earnings release, which delivered multiple positive surprises. Revenue beat consensus by 4.60% with 6.6% year-over-year growth, while the earnings surprise was even more pronounced at 14.88%. The company reported record annualized contract value bookings of $74 million in the first half of 2026, explicitly attributed to traction in claims intelligence and artificial intelligence-driven solutions. Management also raised full-year guidance following this outperformance, a signal of confidence in forward momentum. For a healthcare technology company focused on cost transparency and affordability, the combination of beat earnings, record bookings, AI-driven growth narrative, and raised guidance creates a textbook positive catalyst for a substantial single-day move.

HCWC

Healthy Choice Wellness Corp.Consumer Defensive

$0.30+$0.05

+22.3%

NYSE · Mkt cap $7.4 M

Healthy Choice Wellness Corp. announced a merger with Host Digital Infrastructure LLC and filed a definitive proxy statement for a special stockholder meeting, likely triggering the 22.35% rally as the market reacted to the M&A transaction.

The most recent headline from August 7, 2026 discloses that HCWC filed a definitive proxy statement in connection with a merger with Host Digital Infrastructure LLC and is scheduling a special meeting of stockholders. This is a concrete M&A event. The company transitioned from a natural and organic grocery focused holding company to pursuing a merger with a digital infrastructure entity, which may signal strategic repositioning or potential value creation that the market is pricing in positively. The second headline from August 6 mentioning HCWC in a watchlist of microcap nutrition and wellness plays provides context on investor interest but does not itself explain today's move. The +22.35% jump on the proxy filing date is consistent with a significant corporate action announcement driving intraday trading volume and sentiment.

ARCT

Arcturus Therapeutics Holdings IncHealthcare

$7.41+$1.33

+21.8%

NASDAQ · Mkt cap $233 M

Arcturus reported Q2 earnings and revenue that beat analyst expectations by 21.50% and 18.03% respectively, plus completed enrollment in a Phase II rare disease study, driving the 21.79% single-day gain.

The headlines establish that Arcturus released Q2 2026 financial results on August 6th after market close, delivering a substantial earnings surprise of +21.50% and revenue beat of +18.03%. The company also announced completion of enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, a clinical milestone for its rare-disease pipeline. For a biotech or mRNA therapeutics company with a development-stage focus, beating earnings and revenue estimates simultaneously while advancing pipeline progress typically drives meaningful positive sentiment. The combination of financial outperformance and clinical progress on the same day, reported after hours, would naturally translate into the observed 21.79% gain on August 7th as investors repriced the stock at open. The magnitude of the move is consistent with biotech sector volatility and the double-positive catalyst of financial and clinical news.

RMCO

Royalty Management Holding CorporationFinancial Services

$2.92+$0.52

+21.7%

NASDAQ · Mkt cap $43 M

No news headlines were found in the last 48 hours for RMCO, so the 21.67% gain likely reflects a delayed market reaction to an untracked announcement, technical factors, or speculation in a small-cap stock.

The absence of any recent headlines in the Yahoo Finance RSS feed for RMCO over the past two days makes it impossible to identify a specific catalyst for the sharp 21.67% price jump. Royalty Management Holding Corporation is a small-cap NASDAQ stock, and such names are often subject to amplified price swings driven by technical momentum, low trading volume, short-covering rallies, or market reaction to news that may not have been immediately indexed by major news feeds. Without access to earnings reports, earnings guidance changes, acquisition announcements, contract wins, or other fundamental catalysts, the most honest assessment is that we lack sufficient visibility into what drove the move. The timing gap between the gain and available news coverage could indicate either a delayed news pickup or a purely technical or sentiment-driven move.

NTRA

Natera IncHealthcare

$322.30+$56.92

+21.4%

VIVS

Organovo Holdings, Inc.Healthcare

$0.46+$0.07

+21.3%

NASDAQ · Mkt cap $1.1 M

VivoSim Labs announced a financial and listing compliance update on August 6, likely addressing prior regulatory concerns, which appears to have triggered the 21% rally as investors responded positively to news of restored compliance or improved financial clarity.

The headline references a "Financial and Listing Compliance Update" from VivoSim Labs, a provider of 3D human cellular models for preclinical safety testing. The company trades on Nasdaq under ticker VIVS. The timing of this announcement on August 6 immediately preceding the August 7 price jump, combined with the focus on "listing compliance," suggests the update may have resolved or clarified a prior delisting risk or regulatory concern that had weighed on the stock. Biotech and medical device companies trading at low price points are often sensitive to compliance status changes. However, the headline snippet provided is incomplete and does not disclose the specific content of the update—whether it involves capital raise, debt restructuring, operational metrics, or simply confirmation of continued listing eligibility. This limits the precision of the causal claim.

AREC

American Resources CorpIndustrials

$2.74+$0.48

+21.0%

NASDAQ · Mkt cap $282 M

American Resources' subsidiary ReElement Technologies successfully commissioned its first commercial-scale germanium production column at its Marion facility on August 7, validating the scalability of its refining platform and driving a 21% gain in AREC stock.

The news is specific and timely. ReElement, a minority-held affiliate of American Resources, achieved a key operational milestone by successfully demonstrating commercial-scale germanium production using its proprietary chromatography-based refining platform. This validates proof-of-concept at production scale, a critical de-risking event for companies developing advanced materials and critical minerals processing. The CFO commentary reinforces confidence in the milestone. The broader market backdrop of a weaker-than-expected jobs report also supported risk appetite, with equities rallying on Fed rate easing expectations, but the stock-specific news appears to be the primary driver of the outsized 21% outperformance relative to the index gains shown in the headlines.

NXTC

NextCure IncHealthcare

$5.88+$1.08

+20.5%

NASDAQ · Mkt cap $31 M

NextCure announced a proposed merger with Avere Therapeutics on August 6, which triggered a 20.5% rally as the market reacted to this significant corporate restructuring and capital preservation strategy.

The headline from August 6 reports that NextCure provided a business update and second quarter 2026 financial results, with the centerpiece being a proposed merger with Avere Therapeutics. The company stated it is preserving capital in support of the merger closing while continuing clinical transition and legacy asset activities. Merger announcements typically generate substantial stock moves, either positive or negative, depending on perceived terms, strategic fit, and investor sentiment toward the combined entity. A 20.5% single-day gain suggests the market views this merger favorably, possibly because it represents a capital-efficient path forward, addresses cash burn concerns, or promises complementary assets or capabilities. Without details on merger terms, valuation, or the rationale beyond the headline, we cannot pinpoint whether the optimism stems from Avere's specific pipeline, synergies, or simply relief that management is taking proactive restructuring action.

FERAR

Fifth Era Acquisition Corp I Rights

$0.27+$0.05

+20.5%

NASDAQ

No news headlines were published in the last 48 hours, so the 20.45% jump cannot be attributed to a specific announced event. FERAR is a SPAC rights offering, which can move on M&A speculation, insider activity, or technical trading.

The absence of recent news makes it impossible to pinpoint a concrete catalyst for today's gain. FERAR is a Fifth Era Acquisition Corp rights unit, a blank-check acquisition vehicle. SPAC rights typically trade on market sentiment surrounding potential merger targets, redemption dynamics, or insider transactions that may not be immediately picked up by major news feeds. The 20.45% move could reflect renewed interest in the underlying blank-check entity, speculation about an imminent merger announcement, or technical factors such as short covering or algorithmic trading. Without corroborating headlines or SEC filings visible in the provided data, any specific explanation remains speculative.

FIVN

Five9 IncTechnology

$33.99+$5.69

+20.1%

HALO

Halozyme Therapeutics IncHealthcare

$103.09+$17.20

+20.0%

NASDAQ · Mkt cap $13 B

Halozyme surged 20% after posting record Q2 revenue and EPS that both beat Wall Street expectations by 17-25%, raising full-year guidance on strong ENHANZE platform growth.

The headline evidence is unambiguous and comprehensive. Halozyme released Q2 2026 earnings on August 6 that delivered material beats on both revenue (17.44% above estimates) and EPS (25.28% above estimates), with reported sales climbing 47.7% year-over-year to $481 million. The company raised its full-year 2026 financial guidance the same day. Multiple financial news outlets highlighted the strength of the beat and the company's optimism about incremental growth from its ENHANZE drug-delivery platform and newer product launches, generating what analysts termed bullish Wall Street commentary. The stock hit a record high on August 7 during what the market broadly experienced as a positive trading day for biotech, though HALO's 20% gain clearly outpaced sector averages and reflects the magnitude of the earnings surprise and guidance raise rather than sector tailwinds alone.

NOMA

NOMADAR Corp.Consumer Cyclical

$3.17+$0.53

+19.9%

NASDAQ · Mkt cap $38 M

No news headlines were found in the last 48 hours for NOMA, so the 19.92% gain cannot be directly attributed to a disclosed catalyst; the move likely reflects technical trading, delayed news dissemination, or market rumors.

The absence of recent news headlines on Yahoo Finance is notable given NOMA's strong daily performance as the 50th biggest gainer. This gap does not rule out an actual catalyst—news may exist on other platforms, company channels, or social media before reaching major RSS feeds, or the move could be attributable to intraday technical factors, short-covering, or retail momentum in a lower-liquidity stock. Smaller-cap or less-covered stocks like NOMADAR Corp. often experience outsized moves on thin trading volume driven by sentiment rather than reported fundamentals. Without access to the stock's market cap, float, short interest, or trading volume data, or confirmation of any event, assigning a specific cause is impossible. The most probable categories are a delayed earnings report, a clinical trial result or partnership announcement, or technical/algorithmic buying, but these remain unconfirmed hypotheses.

Biggest Losers

Fri, Aug 7, 2026 50

ARCI

Appliance Recycling Centers of America IncFinancial Services

$0.44−$9.72

-95.7%

AACI

Armada Acquisition Corp. IFinancial Services

$2.73−$7.27

-72.7%

NASDAQ · Mkt cap $341 M

No news headlines were found in the last 48 hours, so the 72.70% crash cannot be attributed to a specific announced event. AACI, a SPAC, may have suffered a sharp repricing due to deal termination, redemption spike, or adverse market conditions.

The absence of recent news makes direct causation impossible to establish. However, Armada Acquisition Corp. I is a blank-check company (SPAC), a security class prone to sharp repricing events even without press coverage. Common triggers include failed merger negotiations, shareholder redemption announcements that trigger liquidation mechanics, insider selling signals, or regulatory delays on a pending business combination. SPACs typically trade near net asset value when a deal is at risk or in wind-down, so a 72.70% drop could reflect either a deal collapse becoming evident through filing rather than headline, or a sudden redemption threshold breach that forces liquidation. Without headlines or SEC filings visible in this data, the precise catalyst remains opaque.

Skycorp Solar Group Limited Ordinary SharesEnergy

$3.18−$4.96

-60.9%

NASDAQ · Mkt cap $5.4 M

PN Smart Energy announced a $5 million registered direct offering on August 7, which typically signals dilution and near-term equity issuance, likely triggering the 61% intraday collapse as investors sold on dilution fears and demand weakness.

The timing and nature of the pricing announcement strongly suggest dilution-driven selling. A registered direct offering of $5 million priced and announced on the same day the stock crashed 61% is a classic catalyst for equity sell-offs, as existing shareholders face immediate dilution and the market interprets the capital raise as a sign of weak balance sheet or poor operating cash flow. The prior day's news about U.S. localization and new subsidiaries appears neutral and was already in the market; the direct offering announcement is the new catalyst. The pricing details (share count, price) are not fully provided in the headline, but the act of raising capital at market in a growth-stage renewable energy company typically pressures shares when announced, especially if the offer is deemed to be priced at a discount to preceding trading prices or if it signals the company lacks operational cash generation.

MYSEW

MYSEWTechnology

$0.01−$0.01

-51.0%

NASDAQ

No news headlines were published in the last 48 hours, so the cause of MYSEW's 50.95% drop cannot be determined from the available evidence. The decline is likely tied to company-specific or technical factors not captured in the news feed.

Yahoo Finance returned zero headlines for MYSEW in the 48 hours preceding this dramatic 51% loss, making it impossible to point to a specific catalyst such as earnings, guidance, regulatory action, or corporate events. For a stock trading at $0.01 on NASDAQ, likely explanations include reverse stock splits, dilutive capital raises, bankruptcy concerns, or failed clinical trials if it is a biotech name, but without news or public filings in the window provided, these remain speculative. The absence of news coverage itself may indicate limited analyst attention or liquidity, which is common in low-priced securities. A delay between SEC filing and news aggregation, or an after-hours development not yet picked up by RSS feeds, is also possible.

FCUV

Focus Universal, Inc.Technology

$5.04−$3.04

-37.6%

NASDAQ · Mkt cap $5.7 M

A 37.62% single-day crash in FCUV stock occurred despite the company announcing it will showcase AI technology at an investment conference, suggesting the move was likely driven by a separate negative catalyst not reflected in the provided headlines or a broader market/sector downturn.

The only headline provided is a standard press release about Focus Universal presenting at the H.C. Wainwright investment conference on August 6, 2026, which is a promotional event typically viewed as neutral to slightly positive for small-cap tech companies. This announcement does not explain a 37.62% single-day decline. The crash likely resulted from one of several unstated events: a negative earnings report, disappointing guidance, loss of a major customer or contract, insider selling, a significant debt or dilutive financing announcement, adverse regulatory action, or broad sector weakness in IoT/5G stocks. Alternatively, this could reflect a technical breakdown or delayed reaction to news released outside the provided 48-hour window. Without access to the actual catalyst, any specific explanation remains speculative.

SEZL

Sezzle Inc. - Common StockFinancial Services

$118.59−$60.35

-33.7%

NASDAQ · Mkt cap $3.8 B

Sezzle crushed Q2 earnings and raised full-year guidance, but stock plummeted 33.73% on investor disappointment with cautious second-half revenue growth outlook, a classic "sell the news" event despite operational strength.

The headline evidence is unambiguous: Sezzle reported record Q2 2026 results on August 6-7, beating both earnings and revenue estimates by roughly 19% and 15% respectively. The company posted 51.7% year-over-year revenue growth to $149.7 million, 37.9% GMV growth, a 76.4% increase in active subscribers to 854,000, and raised full-year 2026 guidance. Despite these metrics, shares fell 22-23% in premarket and continued to around 33.73% by close. Multiple headlines explicitly attribute the selloff to "cautious H2 guidance" and "growth outlook disappointment," indicating that while near-term results beat, management's second-half revenue growth forecast fell short of investor expectations. This is a textbook earnings-driven valuation reset where strong current performance was overshadowed by perceived deceleration ahead. The broader market rally (Nasdaq leaping as Fed rate hike odds sink) provides no offsetting support.

BIGC

BigCommerce Holdings IncTechnology

$2.22−$1.05

-32.1%

NASDAQ · Mkt cap $166 M

No news headlines were found in the last 48 hours, so the 32% drop likely stems from earnings disappointment, analyst downgrade, broader market weakness in SaaS or e-commerce platforms, or undisclosed company-specific developments.

BigCommerce is a software-as-a-service platform serving small to mid-market e-commerce merchants, a category historically sensitive to growth deceleration, margin compression, and macro spending pullbacks. The absence of any news in the last 48 hours is notable given the severity of the move, suggesting either that the catalyst emerged before the snapshot window, trading reflected a delayed market reaction to an earlier announcement, or sentiment shifted on technical or sector-driven factors. Common drivers for SaaS declines of this magnitude include quarterly earnings misses, guidance reductions, customer churn signals, competitive pressure, or deteriorating macroeconomic indicators affecting small business spending. Without specific headlines, we cannot pinpoint which category applies to BIGC on this date.

MEDS

Trxade Group IncHealthcare

$1.96−$0.85

-30.9%

NASDAQ · Mkt cap $4.4 M

No news headlines were found in the last 48 hours to explain MEDS' 30.91% drop, so the cause remains unclear from available sources; the decline may reflect earnings disappointment, analyst downgrade, sector weakness, or technical/liquidity factors.

Despite a severe single-day loss ranking MEDS among the day's eight biggest losers, no recent news articles are available to identify a specific catalyst. This absence of reported news does not rule out material developments; small-cap pharma and healthcare companies sometimes experience sharp moves on unconfirmed rumors, delayed press releases, or reduced analyst coverage. For a micro-cap trading near $2, liquidity constraints and technical selling can amplify downward moves. Common drivers for this sector include clinical trial setbacks, regulatory delays, cash burn concerns, or insider selling. Without headlines or structural insight into MEDS' current positioning, the root cause cannot be pinned down. The timing and magnitude suggest something material occurred, but the evidence to confirm what is simply absent.

CVRX

CVRx, Inc.Healthcare

$2.37−$0.97

-28.5%

NASDAQ · Mkt cap $75 M

CVRx reported Q2 revenue growth and beat estimates but slashed full-year guidance due to sales force turnover, slower productivity, and payer reimbursement headwinds, triggering the sharp 28% sell-off.

CVRx released second-quarter earnings on August 6-7, 2026, posting a modest revenue beat of 0.40% over estimates and 16% year-over-year revenue growth with improved gross margins. However, the company simultaneously lowered its full-year 2026 outlook, citing three material operational challenges: sales force turnover, slower-than-expected productivity ramps for new sales staff, and reimbursement pressures from a major payer (reportedly Medicare/Medicaid). While the quarter's headline numbers were marginally positive, the forward guidance cut and explicit discussion of execution friction in the sales organization signaled to the market that near-term growth momentum is at risk despite strong top-line comparisons. This type of divergence between backward-looking beats and forward-looking caution typically triggers sharp repricing in growth-dependent medical device stocks.

ONFO

Onfolio Holdings Inc. Common StCommunication Services

$0.04−$0.02

-28.2%

NASDAQ · Mkt cap $334 K

Onfolio Holdings announced a 1-for-50 reverse stock split to regain Nasdaq compliance, which typically signals financial distress and dilution concerns that triggered the 28% single-day decline.

The company announced on August 6 that it will execute a 1-for-50 reverse stock split to restore compliance with Nasdaq's minimum bid price requirement, reducing outstanding shares to approximately 850,000. Reverse stock splits are generally perceived negatively by markets because they signal a company in financial difficulty that has fallen below exchange minimum price thresholds. While a reverse split mechanically adjusts share count without changing ownership percentages, investors often interpret it as an admission of weakness and a precursor to further dilution or adverse business developments. The timing of the announcement (August 6) and the sharp decline the following trading day (August 7) aligns with market digestion of this news. The fact that Onfolio needed this action underscores underlying operational or financial challenges that likely drove the stock price below $2.00 (the typical Nasdaq minimum) in the first place.

ASPCR

A SPAC III Acquisition Corp.

$0.11−$0.04

-26.7%

NASDAQ

No news headlines were found in the last 48 hours to explain the 26.67% drop in ASPCR, a SPAC acquisition vehicle trading at $0.11, suggesting the move may be driven by technical factors, illiquidity, or delayed market reaction to prior events.

ASPCR is a blank-check acquisition company, a security class prone to sharp moves on modest volume given their low liquidity and speculative nature. The absence of any news headlines in the past 48 hours means the catalyst for today's decline is not immediately apparent from public announcements. For a SPAC trading near penny-stock levels, typical drivers of sharp declines include reduced merger probability, failed deal negotiations, shareholder redemptions, or simply thin trading on a single-block sale. The extreme rank as the eleventh biggest loser despite the lack of identifiable news also suggests this may be a technically-driven or volume-driven move in a highly illiquid name rather than a fundamental catalyst.

LASR

nLight IncTechnology

$56.16−$19.39

-25.7%

NASDAQ · Mkt cap $2.4 B

nLIGHT beat Q2 earnings and revenue estimates with record defense sales, but issued weak Q3 guidance of $68 million revenue and disclosed China-linked supply chain constraints that are expected to impact shipments, triggering the sharp selloff despite the beat.

The earnings headlines present a classic beat-and-lower-guidance scenario. nLIGHT delivered Q2 revenue of $82.59 million, up 33.8% year-over-year, and beat both earnings and revenue estimates by 7.14% and 5.19% respectively. However, the company guided Q3 revenue to approximately $68 million, which represents a sequential decline and signals deceleration. The earnings call revealed that while defense and aerospace demand reached record levels, management disclosed supply-chain constraints tied to China-linked materials delays that will constrain Q3 shipments. This is a classic growth-stock dynamic: near-term earnings beat overshadowed by forward guidance miss and near-term operational headwinds. The 25.66% drop suggests the market is pricing in both the Q3 revenue miss and broader concerns about supply chain risk duration.

AQB

AquaBounty Technologies IncConsumer Defensive

$1.18−$0.40

-25.3%

NASDAQ · Mkt cap $6.8 M

AquaBounty announced an expansion of its strategic review to include power infrastructure development, but the headline itself does not explain the sharp 25% drop; market reaction likely reflects concern about the company's pivot away from core aquaculture business or skepticism about the feasibi…

The August 6 headline announces that AquaBounty is broadening its strategic alternatives review to encompass power infrastructure opportunities, in addition to its existing aquaculture operations. This is a significant strategic announcement, but the headline alone does not disclose any negative catalyst such as missed earnings, failed facility launch, regulatory setback, or financing issues. The 25% drop the following day suggests the market's interpretation is unfavorable. Reasonable inferences include concern that the company is diversifying away from its core genetically modified salmon business due to operational or market challenges, or skepticism that power infrastructure development is a credible growth path for an aquaculture firm. Alternatively, the announcement may signal financial distress if a broadened strategic review typically precedes asset sales or restructuring. Without additional detail on the company's financial condition, facility performance, or management commentary on why this pivot is necessary, the precise cause remains partially opaque.

JCIC

Jack Creek Investment Corp.

$1.26−$0.43

-25.2%

BAER

Bridger Aerospace Group Holdings, Inc.Industrials

$1.27−$0.42

-24.9%

NASDAQ · Mkt cap $68 M

Bridger Aerospace missed Q2 revenue estimates by 19.75% and reported a significant earnings loss, triggering the 24.93% stock decline despite management reiterating full-year guidance.

The primary catalyst for today's decline is Bridger Aerospace's Q2 earnings report released on August 6, which revealed material underperformance. Revenue of $30.5 million, though flat year-over-year, fell short of analyst expectations by nearly 20 percent. More dramatically, the company reported an earnings surprise of negative 1,200 percent, indicating either an unexpected loss or a sharp deterioration in profitability relative to consensus forecasts. While management cited increasing wildfire activity and longer-duration task orders as positive factors supporting new contracts and geographic expansion, and reiterated full-year 2026 guidance, these forward-looking statements appear insufficient to offset investor disappointment over missed near-term metrics. The market is pricing in the earnings miss as a signal that near-term execution or demand falls short of prior expectations, despite management's confidence in the full-year outlook.

QDEL

Quidel CorpHealthcare

$12.29−$4.07

-24.9%

NASDAQ · Mkt cap $955 M

QuidelOrtho beat Q2 earnings and revenue expectations but slashed full-year revenue guidance and withdrew free cash flow guidance, triggering a 24.86% sell-off as investors repriced the stock on a weaker outlook despite the quarter's performance.

The headlines establish that QuidelOrtho delivered a substantial earnings surprise (+425%) and modest revenue beat (+2.65%) for Q2 2026, with sales of $630.9 million up 2.8% year-over-year. However, the company simultaneously lowered its full-year revenue guidance and withdrew its free cash flow guidance entirely. This combination is classic: a beat on the quarter masks a deteriorated outlook. The company cited continued pressure from China and a softer respiratory testing environment as headwinds, signaling management sees the operating environment worsening. Investors typically penalize forward guidance cuts more heavily than they reward backward-looking beats, especially when the reason is structural demand weakness rather than one-time issues. The stock's 21.6% drop on August 6 followed by continued weakness to 24.86% down suggests the market is repricing earnings power downward based on the revised trajectory.

SOWG

Sow Good Inc.Consumer Defensive

$2.61−$0.86

-24.8%

NASDAQ · Mkt cap $68 M

No news headlines were found in the last 48 hours, so the 24.78% drop cannot be attributed to a disclosed event. The cause could be technical selling, a delayed press release not yet indexed, or unidentified market-moving information.

The complete absence of recent news in the 48-hour window creates significant uncertainty about what drove this steep single-day decline. Sow Good Inc. is a relatively small-cap NASDAQ stock, which makes it more susceptible to volatile moves on lower volume and less institutional coverage. Without earnings releases, guidance changes, regulatory actions, or announced partnerships to point to, the most likely near-term catalysts would typically include sector-wide pressure affecting agricultural or ESG-focused companies, technical chart breaks triggering stop-losses, options expiration dynamics, or an announcement made outside the indexed news feed window. Short-seller activity or adverse social media sentiment could also move a micro-cap stock significantly, though these would not appear in formal news summaries.

HCAT

Health Catalyst IncHealthcare

$1.73−$0.57

-24.7%

NASDAQ · Mkt cap $127 M

Health Catalyst beat Q2 earnings and revenue estimates but reported a 12.7% year-over-year revenue decline to $70.49 million, alongside a strategic asset sale (Vitalware), triggering a 24.75% stock drop despite the earnings beat.

Health Catalyst reported Q2 results that technically exceeded Wall Street expectations on both earnings (100% beat) and revenue (2.33% beat), and the company achieved adjusted EBITDA at the high end of guidance. However, the headline metrics mask a concerning underlying trend: absolute revenue of $70.49 million represents a 12.7% year-over-year decline. Additionally, the company completed the sale of its Vitalware business unit as part of a strategic shift to focus on healthcare intelligence. The sharp sell-off despite the earnings beat suggests the market is reacting negatively to the YoY revenue contraction and/or concerns about the strategic repositioning following the asset sale. Forward guidance expectations (mentioned but not fully detailed in these headlines) may also have disappointed relative to investor expectations.

DSY

Big Tree Cloud Holdings Limited Ordinary SharesConsumer Defensive

$4.70−$1.58

-24.4%

NASDAQ · Mkt cap $18 M

No news headlines were available in the last 48 hours to explain the 24.42% drop, so the cause remains unclear; technical selling, sector rotation, or a delayed announcement are all possible but unconfirmed.

DSY experienced a sharp single-day decline of nearly 25 percent, ranking it among the day's largest losers on NASDAQ. However, no relevant news articles appeared in the Yahoo Finance RSS feed within the 48-hour window before the snapshot date. This absence of reported headlines is notable given the magnitude of the move. For a small-cap cloud services company like Big Tree Cloud Holdings, sharp moves can result from several categories of catalysts: deteriorating quarterly results or guidance, short selling or technical breakdown, sector-wide selloffs in cloud stocks, undisclosed insider news that markets moved on before formal announcement, or liquidity events. Without access to earnings reports, analyst downgrades, SEC filings, or other corporate announcements, we cannot distinguish between these scenarios. The lack of news coverage itself may indicate either that no major corporate event triggered the move, or that the news has not yet been indexed by the feed.

DOCS

Doximity, Inc.Healthcare

$27.39−$8.11

-22.6%

NYSE · Mkt cap $4.7 B

Doximity stock dropped 22.59% despite intraday headlines praising an earnings beat, AI momentum, and raised guidance, suggesting either a delayed negative development, profit-taking after an initial spike, or a disconnect between headline timing and actual market reaction.

The news headlines from August 7 are overwhelmingly positive, describing revenue beats, a 10x return on the new AI search tool, raised fiscal 2027 guidance, accelerating physician engagement, and multiple reports of the stock soaring 38% to 80% during the day. Yet the snapshot shows a 22.59% loss, placing it among the day's worst performers. This contradiction suggests either the positive headlines appeared early in the trading session and were reversed by later negative information not captured in the provided RSS feed, or that profit-taking after an initial euphoric spike gave back gains. It is also possible the snapshot reflects after-hours trading that moved sharply downward post-close. Without access to headlines after the last timestamped article or intraday reversal catalysts, the precise trigger for the late-day collapse cannot be definitively established from the evidence provided.

CTM

Castellum, Inc.Technology

$0.61−$0.18

-22.6%

NYSE · Mkt cap $58 M

CTM dropped 22.6% despite reporting a 10% revenue increase to $28.2M in H1 2026 and a record-year outlook; the sell-off likely reflects investor disappointment with profitability metrics, guidance specificity, or forward growth expectations not meeting market hopes.

Castellum announced solid top-line growth and a strong balance sheet ($16.9M cash, debt-free) alongside a $271.7M backlog, which ordinarily would support a stock price. However, the 22% decline suggests the market focused on metrics not highlighted in the headline—likely net income, margins, or cash flow guidance for the full year. The phrase "expects full year 2026 to be a record year in terms of revenue" is qualitative and non-numeric; if actual full-year guidance disappointed relative to consensus estimates or prior commentary, or if profitability fell short despite revenue growth, investors would sell sharply. Without access to the full earnings release details, the precise margin compression or guidance miss cannot be identified, but the timing (earnings announcement followed by immediate -22% move) firmly points to the earnings report as the trigger rather than external news.

ARKO

Arko Corp.Consumer Cyclical

$5.65−$1.64

-22.5%

NASDAQ · Mkt cap $532 M

ARKO fell 22.5% after missing Q2 earnings estimates by 73% despite announcing a strategic acquisition, suggesting the market punished weak operational results and consumer spending weakness more heavily than it rewarded the growth opportunity.

ARKO reported Q2 2026 results on August 7 with a major earnings miss of 73.33% below estimates, though revenue beat by 18.15%. The earnings call highlighted softer retail demand in June driven by elevated gasoline prices and consumer spending pressure. Management reaffirmed full-year guidance and announced a significant acquisition of U.S. Petroleum Partners to add 280 million gallons of annual wholesale fuel volumes and approximately 30 million dollars of annual adjusted EBITDA. The extreme earnings miss appears to have overshadowed the positive acquisition news. The combination of weak near-term demand signals, margin pressure from fuel price volatility, and a 73% earnings surprise suggests investors are concerned about operational execution and consumer headwinds despite the strategic initiative.

ORGO

Organogenesis Holdings IncHealthcare

$1.86−$0.54

-22.3%

NASDAQ · Mkt cap $246 M

Organogenesis reported a sharp year-over-year revenue decline in Q2 2026 due to ongoing adjustments in the skin substitute market related to Medicare coverage and payment changes, triggering a 22% stock decline.

The two headlines both reference Organogenesis's second-quarter financial results announced on August 6, 2026. The key driver cited is a steep revenue contraction attributed to Medicare and Medicaid coverage and payment policy shifts affecting the skin substitute market. This is a material operational headwind, not a one-time event, as the headlines indicate the market is "continuing to adjust" to these reimbursement changes. The stock's 22% single-day drop reflects investor repricing of the company's near-term growth prospects and margin profile in response to this structural shift in the reimbursement environment. The earnings call and results announcement appear to have disclosed detailed commentary on the revenue decline that prompted the sharp selloff.

TTD

Trade Desk Inc-TheCommunication Services

$13.80−$3.88

-21.9%

NASDAQ · Mkt cap $6.7 B

Trade Desk reported Q2 earnings that missed expectations, issued downbeat Q3 guidance forecasting a 12% revenue decline, and announced major C-suite changes, triggering a 21.93% single-day sell-off attributed to macro and structural concerns.

Trade Desk reported second-quarter revenue of $715 million, up only 3% year-over-year, which fell short of market expectations. The company subsequently issued third-quarter guidance indicating a 12% revenue decline, signaling deteriorating business momentum. This guidance cut, combined with reported pressure from large consumer packaged goods and automotive customers, prompted analyst downgrades and led Wedbush to cite both macro and structural issues with the business. The company also completed a major leadership rebuild over two months, further raising execution concerns. While the broader market rallied on softer-than-expected jobs data reducing rate-hike fears, TTD's company-specific negative catalysts overwhelmed any sector tailwinds, making it the 24th biggest loser despite an S&P 500 record close.

LESL

Leslie''s IncConsumer Cyclical

$1.20−$0.34

-21.9%

NASDAQ · Mkt cap $6.1 M

Leslie's stock fell 21.9% on what appears to be profit-taking or negative sentiment ahead of the company's third quarter 2026 earnings report scheduled for August 12, 2026; the provided headlines only announce the earnings date, not results or guidance.

The sole news item in the 48-hour window is Leslie's announcement that it will report Q3 2026 results on August 12, 2026. This is a routine earnings notification, not a material disclosure about financial performance, guidance, or strategic changes. The sharp 21.9% drop does not align with an ordinary earnings announcement date. Possible explanations include anticipatory selling ahead of expected disappointing results, a negative analyst downgrade or report issued outside the provided headlines, broader sector weakness in discretionary consumer or pool-care stocks, or technical selling pressure in a stock that may have been overbought. Without access to the full news environment or intraday events on August 7, the exact catalyst remains unclear, though pre-earnings concern is a reasonable inference for a stock in a cyclical industry.

XPOF

Xponential Fitness, Inc.Consumer Cyclical

$5.03−$1.36

-21.3%

NYSE · Mkt cap $269 M

Xponential Fitness reported Q2 earnings that badly missed profit expectations with EPS down 77.78% despite slightly beating revenue, triggering the 21% single-day sell-off as investors repriced the stock lower on deteriorating profitability despite modest topline beat.

The earnings report released on August 6, 2026 is the clear catalyst for the stock's decline. While Xponential beat revenue estimates by 1.26%, delivering $65.97 million in Q2 sales, this revenue beat is entirely overshadowed by a massive earnings miss of negative 77.78%, indicating the company reported significantly lower net income or earnings per share than Wall Street expected. The year-over-year revenue decline of 13.4% adds additional concern about growth trajectory. One headline notes the stock dropped 12.5% immediately after hours following the announcement, with the additional decline occurring in the following day's session. For a boutique fitness franchisor, margin compression combined with revenue decline suggests operational challenges that earnings misses of this magnitude typically trigger sharp repricing downward, especially when profitability deteriorates while top-line growth stalls.

TNON

Tenon Medical, Inc.Healthcare

$0.13−$0.04

-21.1%

NASDAQ · Mkt cap $2.4 M

Tenon Medical announced a 1:35 reverse stock split on August 6, which typically signals financial distress or delisting risk; the 21% drop likely reflects investor concern about dilution and the company's underlying condition rather than a fundamental business change.

The headline confirms a reverse stock split announcement dated August 6, 2026, which is a structural corporate action. Reverse splits are usually undertaken when a stock trades below exchange minimum price thresholds to avoid delisting, and they are generally viewed negatively by markets because they do not create economic value—they simply consolidate shares. While the split itself is mechanically neutral to shareholders' pro-rata ownership, the announcement signals the company has been trading at dangerously low levels and faces regulatory pressure. Investors often interpret reverse splits as a sign of financial stress, poor operational performance, or a last-ditch effort to maintain listing status. The 21% decline on the day following the announcement reflects this negative sentiment, though the news headline does not provide details on whether the company disclosed concurrent financial troubles, burn rate concerns, or clinical setbacks.

HUSN

Hudson Capital Inc.

$2.74−$0.73

-21.0%

IIIV

I3 Verticals IncTechnology

$17.41−$4.56

-20.8%

NASDAQ · Mkt cap $461 M

i3 Verticals dropped 20.76% after reporting Q3 earnings that missed expectations and cutting full-year guidance, despite strong SaaS revenue growth, due to weakness in professional services and transaction revenue headwinds.

The company released third-quarter fiscal 2026 results on August 6–7, 2026 that fell short of management's own expectations, prompting a full-year outlook reduction. While the headlines note a 38% surge in SaaS revenue and AI-driven efficiency gains as positive offsets, the guidance cut and cited weakness in professional services and transaction revenue represent material deterioration in near-term performance. For a payments and software company, transaction revenue weakness is particularly concerning as it signals slower customer activity or adoption. The magnitude of the sell-off (29th largest loser of the day) aligns with the severity of a guidance miss and cut, which typically triggers algorithmic and institutional selling regardless of longer-term SaaS tailwinds.

WEAV

Weave Communications, Inc.Healthcare

$5.30−$1.35

-20.3%

NYSE · Mkt cap $586 M

Weave posted a strong Q2 earnings beat with 15.5% revenue growth and expanding margins, but the stock plunged 20.3% anyway, suggesting the market's reaction reflects either guidance disappointment, the "temporary sales model disruption" mentioned, or a broader market repricing unrelated to the ea…

The headline evidence presents a puzzle: Weave exceeded both earnings estimates (+33% beat) and grew revenue 15.5% with improving operating margins. By conventional metrics, this should support the stock. However, the 20% intraday collapse indicates the market focused on different details. The earnings call highlights specifically mention "a temporary sales model disruption" that management is navigating. This phrase likely signals a near-term revenue or customer acquisition headwind that overshadowed the strong historical results. Alternatively, forward guidance may have been cautious or the company may have raised concerns about the sustainability of growth. Without access to the full earnings call transcript or guidance metrics, we cannot confirm which specific disclosure drove the reversal, but the phrase "temporary" suggests management acknowledged a material operational challenge that the market penalized heavily.

INHD

Inno Holdings Inc.Basic Materials

$5.19−$1.78

-20.2%

NASDAQ · Mkt cap $36 M

INHD fell 20.17% with no news disclosed in the last 48 hours, making the specific cause unknown; the drop likely stems from a delayed announcement, technical selling, or market-wide sector pressure.

No headlines were found in the Yahoo Finance RSS feed for the past 48 hours, so there is no news event on record to explain the 20 percent decline. This absence of information is itself notable given the magnitude of the move. For a stock experiencing a drop of this size, the underlying cause typically falls into one of several categories: a negative earnings or revenue report released outside the monitored news window, an unannounced insider transaction or short-seller report, deterioration in a key business metric, sector-wide contagion, or technical momentum reversal from previous gains. Without access to company filings, regulatory announcements, or social media activity beyond the headlines provided, pinpointing the specific catalyst is not possible from the available evidence.

FWACW

Futurewave Acquisition Corporation Warrants

$0.04−$0.01

-20.0%

DSX.WT

Diana Shipping Inc. WT

$0.28−$0.07

-20.0%

NATR

Nature's Sunshine Products IncConsumer Defensive

$16.37−$3.92

-19.3%

NASDAQ · Mkt cap $256 M

Nature's Sunshine reported record Q2 sales of $117 million but missed revenue expectations and lowered full-year guidance due to FX headwinds and China weakness, triggering a 19.32% stock decline.

The earnings release on August 6 presented a mixed picture that the market viewed negatively. While NATR achieved its strongest Q2 in company history with $117 million in net sales and improved gross profit margin to 73.7%, the headline metrics disappointed relative to market expectations. The company's sales rose only 1.9% year-over-year, missing consensus revenue targets, and management lowered full-year guidance citing foreign exchange headwinds and weakness in China, a key market for the company. The appointment of a new CFO (Ruth Perkins) announced simultaneously may have added uncertainty. For a nutritional supplements company, China exposure and FX sensitivity are material risks, and forward guidance reductions typically trigger sharp selloffs regardless of historical quarterly performance. The market appears to have focused on the miss and the guidance cut rather than the record sales figure.

AMIX

Autonomix Medical, Inc. Common StockHealthcare

$10.01−$2.33

-19.3%

NASDAQ · Mkt cap $5.7 M

No news headlines were found in the last 48 hours, so the 19.27% decline cannot be directly attributed to a specific announced event; the move likely reflects either delayed market reaction to earlier news, technical selling, or sector-wide pressure.

The absence of recent headlines makes pinpointing the exact cause difficult. Autonomix Medical is a medical device company, and sharp single-day declines in this sector typically stem from clinical trial setbacks, regulatory delays or rejections, guidance cuts, insider selling, or short-squeeze reversals. It is also possible the decline reflects a delayed market reaction to news released before the 48-hour window, or technical deterioration triggered by a breach of key support levels or options expiration dynamics. Without confirmed information, any specific cause remains speculative. The stock's ranking as the 35th biggest loser suggests this was a material but not extraordinary move, which could indicate sector rotation or profit-taking rather than a catastrophic company-specific event.

PTSI

PAM Transportation Services IncIndustrials

$14.18−$3.38

-19.2%

NASDAQ · Mkt cap $262 M

No news headlines were found in the last 48 hours, so the 19.25% drop cannot be directly attributed to a specific company announcement or event. The decline likely stems from technical selling, broader market conditions, or unvetted rumors.

PAM Transportation Services experienced a sharp single-day loss without accompanying news in the available Yahoo Finance RSS feed. This absence of headline coverage during a major move is itself informative but incomplete. PTSI is a small-cap trucking and transportation services provider, a sector sensitive to fuel costs, freight demand cycles, economic outlook shifts, and interest rates. The stock could have reacted to negative analyst commentary, an earnings miss released outside the standard news cycle, a guidance reduction, deteriorating freight market conditions, or negative commentary on the trucking sector broadly. Alternatively, the move could reflect technical breakdown, short covering reversal, or delayed market reaction to company-specific news not yet captured in the RSS snapshot provided.

ASIX

AdvanSix IncBasic Materials

$16.42−$3.73

-18.5%

NYSE · Mkt cap $460 M

AdvanSix reported Q2 2026 earnings on August 7th, and the stock dropped 18.51%, suggesting the results or forward guidance disappointed investors significantly.

The only headline provided is the Q2 2026 earnings call summary posted the same day as the sharp decline. While the headline itself does not detail specific metrics, beats, misses, or guidance changes, the timing is decisive: a nearly 19% single-day drop on the exact day earnings were released points overwhelmingly to earnings-driven disappointment. This could reflect lower-than-expected revenue or profits, downward guidance revision, margin compression, or negative commentary on industry conditions. Without access to the actual earnings numbers or call transcript, the precise reason cannot be stated, but the causation chain (earnings day = big drop) is clear.

CABR

Caring Brands, Inc.Healthcare

$1.33−$0.30

-18.4%

NASDAQ · Mkt cap $12 M

Caring Brands fell 18.4% on an intellectual property portfolio update announced after market close on August 6, but the content of that update—mentioning five issued patents and $20B+ market opportunity—does not explain a sharp sell-off without additional context.

The only news provided is an intellectual property portfolio update released on August 6 at 20:05 UTC that highlights five issued U.S. patents and references large addressable markets in dermatology and hair care. On its face, a patent portfolio announcement typically supports investor sentiment rather than triggering an 18% decline. The headline snippet is incomplete, cutting off mid-sentence, so material details may be missing. Possible explanations include: the full release contained disappointing information about patent scope, commercialization delays, or competitive challenges not captured in the truncated headline; or the market reaction reflects broader concerns about execution risk, cash runway, or dilution that preceded the announcement. Without the full text or contemporaneous trading context, the causal link between this news and the sharp drop remains unclear.

ADIL

Adial Pharmaceuticals IncHealthcare

$3.99−$0.90

-18.3%

NASDAQ · Mkt cap $15 M

No news headlines were found in the last 48 hours, so the 18.34% drop on ADIL cannot be directly attributed to a reported event. The decline likely reflects technical selling, broader market weakness, or an unreported development in this small-cap biotech stock.

The absence of news in the Yahoo Finance RSS feed over the past two days makes it difficult to pinpoint a specific catalyst for ADIL's sharp 18.34% decline. Small-cap pharmaceutical stocks like Adial are typically sensitive to clinical trial results, regulatory decisions, cash position announcements, or licensing deals—events that could easily move the stock significantly. Given the lack of reported headlines, the move could stem from several sources: technical selling pressure or chart-driven trading common in volatile microcap names, deterioration in market sentiment toward speculative biotech plays, an internal corporate announcement not yet picked up by major news services, or delayed reaction to earlier news. Without substantive information linking the decline to a specific corporate action or external event, the underlying cause remains unclear.

ARDX

Ardelyx IncHealthcare

$3.99−$0.88

-18.0%

NASDAQ · Mkt cap $981 M

Ardelyx reported record Q2 revenue of $118M (31% growth) but missed earnings estimates by 40% and slashed 2026 IBSRELA guidance due to payer obstacles, triggering an 18% sell-off despite the revenue beat.

The headline evidence establishes a classic earnings disappointment: while Ardelyx delivered record absolute revenue ($118.1M, up 31% YoY) driven by IBSRELA ($86.2M) and XPHOZAH ($31.9M), the company missed consensus earnings estimates by 40% and fell short of revenue expectations by 2.27%. More critically, management lowered full-year IBSRELA guidance and withdrew XPHOZAH guidance entirely, citing payer-imposed access challenges. Analysts immediately added ARDX to the Zacks Strong Sell list on August 7th. The market penalized the stock for forward guidance cuts and profitability concerns despite topline strength, a common pattern when high-growth companies signal margin or reimbursement headwinds ahead. The 18% drop reflects the guidance cut and earnings miss overriding the positive revenue surprise.

CIA

Citizens Inc-TXFinancial Services

$3.78−$0.80

-17.5%

NYSE · Mkt cap $196 M

Citizens Inc reported second quarter 2026 financial results on August 6, and the stock fell 17.47% the next day, suggesting the earnings or guidance disappointed the market.

The headline confirms that Citizens Inc released Q2 2026 financial results on August 6 at 20:05 UTC, just before the trading day that produced this sharp 17.47% decline. The company is described as a diversified financial services firm focused on life insurance, living benefits, and final expense insurance. However, the headline provided is only a press release header and does not include the actual financial metrics, earnings per share, revenue figures, guidance changes, or management commentary that would explain investor reaction. For an insurance company, typical negative catalysts include underwriting losses, reserve increases, regulatory pressures, or reduced forward guidance. Without access to the full earnings statement or analyst consensus before and after the release, we cannot definitively identify which metric disappointed, but the timing strongly suggests the earnings announcement itself was the proximate cause of the selloff.

IGACR

Invest Green Acquisition Corporation Rights

$0.16−$0.03

-17.3%

NASDAQ

No news headlines were found in the last 48 hours to explain the 17.26% drop in IGACR, a SPAC rights offering that is inherently volatile and illiquid due to its structure.

The absence of any news in the last 48 hours means we cannot point to a specific catalyst such as earnings, a merger announcement, regulatory action, or guidance change. IGACR is a rights offering tied to Invest Green Acquisition Corporation, a special purpose acquisition vehicle. Rights offerings are typically highly illiquid instruments with minimal trading volume, making them prone to sharp percentage moves on very small dollar volume shifts or redemption activity. The 17.26% decline could reflect routine SPAC redemption pressure, a shift in market sentiment toward the underlying blank-check sponsor or its potential merger target, or simply thin-volume trading mechanics. Without news or volume context, distinguishing between these scenarios is not possible.

AKAM

Akamai Technologies IncTechnology

$110.51−$22.59

-17.0%

NASDAQ · Mkt cap $15 B

Akamai beat Q2 earnings and landed $2.8 billion in contracts, but the 17% sell-off reflects investor disappointment that strong cloud growth cannot offset shrinking profit margins and weakness in legacy delivery services despite the positive headline numbers.

Akamai reported Q2 2026 earnings and revenue that beat analyst estimates and demonstrated strong demand for cloud infrastructure and AI security products, culminating in record $2.8 billion in multi-year contract wins. The stock initially surged 10.5% in after-hours trading on the earnings beat. However, the rally reversed sharply into the close and continued downward on August 7th. The headlines reveal the core issue: while revenues grew 5% year-over-year and cloud infrastructure accelerated, higher infrastructure investments pressured earnings and profit margins contracted. Wall Street's assessment appears to be that the company's strategic pivot toward AI-powered edge computing, though strategically sound, is consuming profitability faster than expected. The new $600 million contract and $2.8 billion commitments are insufficient to overcome concerns about margin compression and legacy service deterioration. This represents a classic growth-at-what-cost rejection where the market values near-term profitability over long-term AI positioning.

AACBR

Artius II Acquisition Inc. Rights

$0.10−$0.02

-16.7%

NASDAQ

No news was reported in the last 48 hours, so the 16.74% decline in AACBR rights likely reflects general warrant/rights volatility or deterioration in the underlying SPAC's prospects or deal dynamics.

AACBR is a SPAC rights offering, a derivative security whose value is highly sensitive to both market sentiment toward the parent SPAC and broader risk appetite shifts. Rights are typically lower-liquidity instruments that trade on wider bid-ask spreads and can experience outsized moves on minimal volume. Without news headlines, the decline could stem from several structural factors: deterioration in confidence around the target acquisition, expiration risk as the rights approach their redemption window, a pullback in the underlying SPAC share price, or simply thin trading liquidity causing technical pressure. SPAC-related securities have seen reduced appetite across 2024-2026 due to regulatory scrutiny and deal completion challenges. The absence of news does not rule out a specific catalyst; it may reflect a delayed market reaction to private developments, shareholder concern, or target news that has not yet been widely reported through major headlines.

RDACR

Rising Dragon Acquisition Corp. Rights

$0.09−$0.02

-16.6%

NASDAQ

No news headlines were found in the last 48 hours, so the 16.57% decline likely reflects either broad market movement in SPAC rights instruments, expiration pressures, or low-liquidity price swings typical of this security class.

Rising Dragon Acquisition Corp. Rights (RDACR) is a SPAC rights offering, a thin-liquidity security that often trades on technical factors and arbitrage dynamics rather than fundamental news flow. The absence of any headlines in the last 48 hours suggests the drop was not driven by company-specific announcements or deal developments. SPAC rights are sensitive to redemption timelines, changes in the underlying SPAC's merger probability or timeline, and market-wide shifts in SPAC sentiment. Given the magnitude of the single-day loss and lack of disclosed catalyst, this move is most likely attributable to either expiration pressure on the rights themselves, reduced demand for SPAC exposure, or normal volatility in a low-volume security with wide bid-ask spreads. Without access to intraday volume or redemption data, the precise trigger remains unclear.

LBGJ

LBGJIndustrials

$3.38−$0.67

-16.5%

NASDAQ · Mkt cap $58 K

No news headlines were published about LBGJ in the last 48 hours, so the 16.47% drop likely stems from technical selling, sector weakness, or undisclosed corporate developments not yet reported by major outlets.

The absence of any recent news in the last 48 hours makes it impossible to tie the sharp 16.47% decline to a specific catalyst. LBGJ could be experiencing technical selling pressure following a price run-up, weakness in its sector or broader market conditions, or an announcement made through other channels not yet picked up by Yahoo Finance's RSS feed. Without knowing the company's fundamentals, business model, or recent trading patterns, plausible triggers could include insider selling activity, a delayed earnings miss, regulatory concerns, or changes in analyst sentiment. The magnitude of the one-day drop suggests something material occurred, but the evidence simply is not available in the headlines provided.

SILO

Silo Pharma Inc.Healthcare

$3.81−$0.75

-16.4%

NASDAQ · Mkt cap $4.5 M

No news headlines were published in the last 48 hours to explain SILO's 16.45% drop, so the cause remains unknown without access to broader market data or company announcements outside this feed.

The absence of any recent news coverage for a stock that ranks as the 47th biggest loser on its trading day is noteworthy and suggests the catalyst either occurred outside the Yahoo Finance RSS feed window, emerged from a non-traditional source, or reflects intraday volatility tied to technical factors or sector weakness. For a small-cap biotech firm like Silo Pharma, typical drivers of large single-day declines include clinical trial setbacks, regulatory rejections, insider selling, analyst downgrades, or shifts in financing prospects. Without headlines to ground analysis, any specific attribution would be speculation. The lack of published news within 48 hours of a 16% drop is unusual and warrants checking company filings, press releases, or investor relations announcements directly to identify the actual trigger.

RPID

Rapid Micro Biosystems, Inc.Healthcare

$1.74−$0.34

-16.4%

NASDAQ · Mkt cap $85 M

Rapid Micro Biosystems reported Q2 earnings on August 7 that beat revenue guidance and delivered record gross margins with 11% growth, but the stock dropped 16.35%, suggesting the market either expected significantly stronger results, faced disappointment on profitability or forward guidance, or …

The headline evidence presents a paradox. RPID reported Q2 2026 revenue of $8.1 million, up 11% year-over-year and above prior guidance, with record gross margin and achievement of a 200th system placement milestone. These are quantitatively positive results. However, one headline explicitly states the company reported a Q2 loss, and the earnings surprise metric showed a negative 3.85% earnings surprise despite a positive 3.26% revenue surprise. The disconnect between revenue upside and earnings miss, combined with a 16% single-day drop, suggests the market focused on profitability weakness, losses that disappointed relative to expectations, or potentially cautious forward guidance or commentary. Without access to the full earnings call transcript or guidance revisions, the precise trigger remains unclear, but the pattern indicates earnings-call-driven disappointment on the bottom-line picture rather than top-line performance.

TONT.WT

Graf Global Corp.

$0.41−$0.08

-16.3%

SXTC

China SXT Pharmaceuticals IncHealthcare

$0.05−$0.01

-16.3%

NASDAQ · Mkt cap $2.4 M

No headlines were published in the last 48 hours to explain the 16.33% drop in SXTC, so the move likely stems from technical selling, a delayed announcement, or broader market pressure on micro-cap biotech stocks.

The absence of any recent news headlines makes it impossible to pinpoint a specific corporate event or catalyst for this move. SXTC is a micro-cap pharmaceutical stock trading at $0.05, a price point typical of highly speculative companies with significant execution risk. Stocks at this valuation tier are sensitive to several common drivers that often occur without formal press releases: technical breakdowns through key support levels, execution of short positions or forced liquidations, delayed announcements of clinical trial results or regulatory decisions, or contagion selling in the broader micro-cap biotech sector. Without access to SEC filings, insider transaction reports, or real-time news wires beyond Yahoo Finance, it is not possible to determine which of these categories best explains today's move.